Novo Nordisk's stocks fell 27% in March, marking its worst performance since July 2002, primarily due to competition from Eli Lilly. The company's share price dropped to 469.8 Danish Krone, a 54% decline from its all-time high in June 2024. Investor concerns were heightened by disappointing trial results for its weight-loss drugs and potential tariffs from US President Donald Trump. Despite recent price cuts for its drug Wegovy, analysts remain optimistic about Novo Nordisk's long-term growth prospects. Teljes cikk (Euronews.com)